[HTML][HTML] A case of bronchial asthma as an immune-related adverse event of pembrolizumab treatment for bladder cancer: a case report
K Hamada, K Yoshimura, K Oshinomi, Y Hirasawa… - Medicine, 2022 - journals.lww.com
Interventions: The patient was treated with betamethasone, montelukast, salbutamol
nebulization, and a combination of salmeterol (50 μg) and fluticasone (500 μg)(SFC).
Outcomes: The patient's wheezing resolved, and her peak flow rate reached 100% of the
predicted value; therefore, the patient continued treatment with SFC and montelukast and
was discharged from the hospital. Conclusion: Increases in CTLA-4 and TIM-3 expression in
CD4+ T cells (not CD8+), as well as an increase in Th17 cells, may reflect asthma-related …
nebulization, and a combination of salmeterol (50 μg) and fluticasone (500 μg)(SFC).
Outcomes: The patient's wheezing resolved, and her peak flow rate reached 100% of the
predicted value; therefore, the patient continued treatment with SFC and montelukast and
was discharged from the hospital. Conclusion: Increases in CTLA-4 and TIM-3 expression in
CD4+ T cells (not CD8+), as well as an increase in Th17 cells, may reflect asthma-related …